AI
Thursday, October 17, 2024 1:03:42 PM
$AMRN Hello Friends,
NHS English Prescribing Data for August 2024 is now in. I’ve prepared 4 slides for you today to illustrate the growth of VAZKEPA® Scripts (Single Doses), in England (Jan. 2022 to August 2024):
Slide #1: Monthly chart and graph showing the growth in VAZKEPA® compared to OMACOR (Omega-3 Ethyl Esters), Bempedoic Acid, and the BA + Ezetimibe Combo Tablet. It appears that VAZKEPA® is increasing scripts at OMACOR’s expense. VAZKEPA® doses increased about 6% vs. July.
Slide #2: A stacked cumulative bar graph that shows total growth of the four LLT products and their relative proportions each month.
Slide #3: This chart and graph show the estimated revenue in British Pounds generated each month from VAZKEPA® scripts which are reimbursed by NHS at 144£ per 30 day script (120 capsules). Since VAZKEPA® launched approximately £3.4 million have been generated.
Slide #4 shows the breakdown of VAZKEPA® scripts by Geographic English Regions. The Midlands produce the bulk of these prescriptions while London is still a noticeable laggard. The UK Team needs to better promote England’s most populated regions (Southeast and London).
LMK if you need any detail from this data.
View the Report here:
https://drive.google.com/file/d/1rOGJsQ_icP5OUkl-Ff3CibgRcJfeY7Ws/view?usp=sharing
NHS English Prescribing Data for August 2024 is now in. I’ve prepared 4 slides for you today to illustrate the growth of VAZKEPA® Scripts (Single Doses), in England (Jan. 2022 to August 2024):
Slide #1: Monthly chart and graph showing the growth in VAZKEPA® compared to OMACOR (Omega-3 Ethyl Esters), Bempedoic Acid, and the BA + Ezetimibe Combo Tablet. It appears that VAZKEPA® is increasing scripts at OMACOR’s expense. VAZKEPA® doses increased about 6% vs. July.
Slide #2: A stacked cumulative bar graph that shows total growth of the four LLT products and their relative proportions each month.
Slide #3: This chart and graph show the estimated revenue in British Pounds generated each month from VAZKEPA® scripts which are reimbursed by NHS at 144£ per 30 day script (120 capsules). Since VAZKEPA® launched approximately £3.4 million have been generated.
Slide #4 shows the breakdown of VAZKEPA® scripts by Geographic English Regions. The Midlands produce the bulk of these prescriptions while London is still a noticeable laggard. The UK Team needs to better promote England’s most populated regions (Southeast and London).
LMK if you need any detail from this data.
View the Report here:
https://drive.google.com/file/d/1rOGJsQ_icP5OUkl-Ff3CibgRcJfeY7Ws/view?usp=sharing
